Literature DB >> 8345202

Recombinant tetravalent group A streptococcal M protein vaccine.

J B Dale1, E Y Chiang, J W Lederer.   

Abstract

Previous studies have shown that the amino-terminal regions of group A streptococcal M proteins contain primarily protective (opsonic) epitopes and not tissue-cross-reactive epitopes. Limited primary structures from multiple serotypes of M protein containing only protective epitopes could potentially be linked together to form a broadly protective vaccine. The present studies were undertaken to determine the protective immunogenicity of a recombinant, multivalent hybrid molecule containing amino-terminal subunits of types 24, 5, 6, and 19 M proteins. Polymerase chain reaction primers were designed to amplify emm gene fragments ranging from 35 to 113 codons. The PCR products were ligated in tandem and inserted into pKK223-3. The tetravalent M protein that was purified from extracts of Escherichia coli migrated as a single band on SDS-PAGE with an apparent m.w. of 31 kDa. In immunoblot analyses, the hybrid protein reacted with serotype-specific antisera indicating that it contained all four M protein subunits. Rabbits immunized with the purified tetravalent M protein developed significant antibody levels against all four serotypes of native M proteins represented in the hybrid protein. None of the antisera cross-reacted with human tissues. The immune sera also opsonized all four serotypes of group A streptococci. Our data show that a hybrid protein containing subunits from multiple M proteins can evoke broadly protective immune responses without tissue-cross-reactive antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345202

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci.

Authors:  E R Brandt; T Teh; W A Relf; R I Hobb; M F Good
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

2.  A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Authors:  Colleen Olive; Michael R Batzloff; Anikó Horváth; Allan Wong; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

3.  Immunogenicity of a 26-valent group A streptococcal vaccine.

Authors:  Mary C Hu; Michael A Walls; Steven D Stroop; Mark A Reddish; Bernard Beall; James B Dale
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

4.  New protective antigen of group A streptococci.

Authors:  J B Dale; E Y Chiang; S Liu; H S Courtney; D L Hasty
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

5.  Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

Authors:  Mary A Hall; Steven D Stroop; Mary C Hu; Michael A Walls; Mark A Reddish; David S Burt; George H Lowell; James B Dale
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

6.  Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells.

Authors:  H S Courtney; J B Dale; D I Hasty
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

7.  Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.

Authors:  Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2007-01-17       Impact factor: 3.641

Review 8.  The new threats of Gram positive pathogens: re-emergence of things past.

Authors:  R A Howe; N M Brown; R C Spencer
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

9.  Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice.

Authors:  S Kawabata; E Kunitomo; Y Terao; I Nakagawa; K Kikuchi; K Totsuka ; S Hamada
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 10.  Current guidelines for the treatment of patients with rheumatic fever.

Authors:  D Thatai; Z G Turi
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.